Advertisement

Combo pill approved for adults with type 2 diabetes

FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.

FDA recently approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride (HCI) extended-release) for adults with type 2 diabetes, according to AstraZeneca.

It is approved as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both dapagliflozin and metformin is appropriate.

Doctors say type 2 diabetes needs more holistic approach

Xigduo XR is the first once-daily tablet combining a sodium glucose co-transporter 2 (SGLT2) inhibitor and metformin HCI extended-release, a biguanide, approved in the United States.

Advertisement

 

“The addition of Xigduo XR to our U.S. diabetes portfolio is further evidence of AstraZeneca’s commitment to develop new treatment options for patients with type 2 diabetes,” said Elisabeth Björk, head of cardiovascular & metabolism, global medicines development, AstraZeneca. “The approval of once-daily Xigduo XR provides prescribers and adult patients with another treatment choice, supporting a more [personalized] approach to disease management.”

Xigduo XR removes glucose from the body through the kidneys.  Click here to read Xigduo XR dosing instructions.


Advertisement
Advertisement